A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination.
Nat Nanotechnol
; 17(9): 993-1003, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2000903
ABSTRACT
The global emergency caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic can only be solved with effective and widespread preventive and therapeutic strategies, and both are still insufficient. Here, we describe an ultrathin two-dimensional CuInP2S6 (CIPS) nanosheet as a new agent against SARS-CoV-2 infection. CIPS exhibits an extremely high and selective binding capacity (dissociation constant (KD) < 1 pM) for the receptor binding domain of the spike protein of wild-type SARS-CoV-2 and its variants of concern, including Delta and Omicron, inhibiting virus entry and infection in angiotensin converting enzyme 2 (ACE2)-bearing cells, human airway epithelial organoids and human ACE2-transgenic mice. On association with CIPS, the virus is quickly phagocytosed and eliminated by macrophages, suggesting that CIPS could be successfully used to capture and facilitate virus elimination by the host. Thus, we propose CIPS as a promising nanodrug for future safe and effective anti-SARS-CoV-2 therapy, and as a decontamination agent and surface-coating material to reduce SARS-CoV-2 infectivity.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Nanostructures
/
COVID-19 Drug Treatment
Topics:
Variants
Limits:
Animals
/
Humans
Language:
English
Journal:
Nat Nanotechnol
Year:
2022
Document Type:
Article
Affiliation country:
S41565-022-01177-2
Similar
MEDLINE
...
LILACS
LIS